University Hospital Leuven (UZ Leuven)
Welcome,         Profile    Billing    Logout  
 10 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maertens, Johan
SAFE, NCT05926063: Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia

Recruiting
4
410
Europe
Comparison short vs extended EBAT treatment group
Universitaire Ziekenhuizen KU Leuven, University Hospital, Ghent, Universitair Ziekenhuis Brussel, University Hospital, Antwerp, AZ Sint-Jan AV, Centre Hospitalier Universitaire de Liege, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Neutropenia, Febrile
07/26
07/26
TRACE, NCT04832607 / 2018-000853-29: Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Recruiting
3
149
Europe
Multivirus (CMV, EBV, AdV)-specific T cells
Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain
AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
06/24
12/24
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
IA-DUET, NCT04876716 / 2020-000627-40: Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Terminated
3
66
Europe
Azole, Voriconazole, isavuconazole, posaconazole, Anidulafungin, Ecalta
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Hemato-Oncologie voor Volwassenen Nederland
Invasive Aspergillosis
05/24
05/24
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
SCYNERGIA, NCT03672292 / 2018-002565-18: Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Terminated
2
22
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Voriconazole, Oral Placebo Tablets, SCY-078 matching Placebo
Scynexis, Inc., SCYNEXIS, Inc.
Invasive Pulmonary Aspergillosis
03/23
03/23
NCT00603330: Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Recruiting
2
100
Europe
Mesenchymal stem cells
University of Liege, KU Leuven, Maastricht University Medical Center, Ziekenhuis Netwerk Antwerpen (ZNA), University Hospital, Antwerp, University Hospital, Ghent, AZ-VUB, AZ Sint-Jan AV, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital of Mont-Godinne, Jolimont Hospital Haine Saint Paul, Queen Fabiola Children's University Hospital
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
08/24
08/24
NCT03852407: Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Recruiting
2
114
Europe
Thymoglobulin, ATG, Melphalan, alkeran, Fludarabine, Cyclophosphamid, PTCy
University of Liege, Belgian Hematological Society
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome, Myeloproliferative Disorder, Acute Lymphoid Leukemia in Remission, Multiple Myeloma, Chronic Lymphoid Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma
11/33
11/38
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
CYCLE-1, NCT04167696: Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting
1
27
Europe, US
CYAD-02, ENDOXAN, cyclophosphamide, Fludara, fludarabine
Celyad Oncology SA
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/21
02/35
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
PTX3 AML, NCT03828773: PTX3-targeted Antifungal Prophylaxis

Recruiting
N/A
320
Europe
Posaconazole, Noxafil, Fluconazole, Diflucan
Bochud Pierre-Yves, Swiss National Science Foundation
Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition, Aspergillosis
11/25
11/25
Goffin, Karolien
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
NCT03327675: High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer

Recruiting
N/A
188
Europe
68Ga-PSMA (HBED-CC) PET
Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
12/25
12/25

Download Options